Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2008

View Archived Issues

BioMarin reports Q4 and full-year 2007 results

Pipeline progress at Antigenics

Roche updates prescribing information for influenza drug Tamiflu

Advanced Cancer signs exclusive license with Brown Cancer Center for anticancer drug

Raven enters research collaboration with Emory University for prostate cancer stem cells

Cypress Bioscience closes acquisition of Proprius for USD 37.5 million in cash

E.U. Commission approves amended prescribing information for Aranesp

DiaMedica receives E.U. regulatory clearance for phase II study of DM-99 in type 2 diabetes

Celgene initiates phase I clinical study of inflammatory disease drug candidate

Microbia and Forest report preliminary results from two phase IIb studies of linaclotide

Promising PET radioligand profiled at the NIH

Neurokinin 1 receptor potential target for the treatment of alcoholism

Study reports new class of selective Plasmodium falciparum inhibitors

ActivBiotics receives FDA orphan drug designation for M-40403 in oral mucositis

EpiCept earns milestone payment from Myriad Genetics for progress in phase II trial of Azixa

Oral PSI-421 treatment effective in primate model of deep vein thrombosis

FDA accepts for review Theravance's response to NDA approvable letter for telavancin

Evotec signs second drug discovery contract with InterMune

New agents for treating urolithiasis disclosed in recent University of Western Ontario patent

FDA agrees with remaining two protocols for Alizyme's phase III clinical studies of cetilistat

Novel antiinfective agents described in recent patent literature

Recent patents divulge new antipsychotic agents

GenVec receives a phase I grant from the NIAID for adenovector-based vaccines for HSV-2

Avanir licenses anthrax monoclonal antibody program to Emergent BioSolutions

Genzyme launches Renvela in the U.S. for dialysis patients and submits MAA to the EMEA

CSL Behring submits BLA to the FDA for Berinert in hereditary angioedema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...